Supriya Lifescience Fixes Record Date for Final Dividend and AGM on Sep 4, 2026
Supriya Lifescience has set September 4, 2026, as the record date for its final dividend payment for FY 2025-26. The company's AGM is scheduled for September 24, 2026, where the final dividend of Re. 1.00 per equity share will be proposed for approval.
The announcement is primarily procedural, confirming the record date for a previously recommended dividend and the date for the AGM. The dividend amount is nominal and subject to approval, thus having a low immediate impact on the company's stock price or business operations.
The announcement is a routine procedural update regarding the record date for dividend payment and the AGM schedule. It does not contain any new financial performance data or strategic shifts that would positively or negatively impact the company's outlook.
Supriya Lifescience Limited has announced that the company has fixed Friday, September 4, 2026, as the Record Date for determining the entitlement of members to receive the final dividend for the financial year 2025-26. This dividend, if approved by the members at the Annual General Meeting (AGM), will be paid within 30 days to those shareholders whose names appear in the Register of Members or Register of Beneficial Owners as of the Record Date.
The Board of Directors, in their meeting held on May 27, 2026, had recommended a final dividend of Re. 1.00 per equity share of Rs. 2/- each for FY 2025-26. This recommendation is subject to the approval of the company's members at the upcoming AGM.
The Eighteenth Annual General Meeting (AGM) of the company for FY 2025-26 is scheduled to be held on Thursday, September 24, 2026, at 3:00 p.m. (IST) through Video Conferencing (VC) or Other Audio Video Means (OAVM). Further details regarding the AGM will be provided in the Notice of AGM, which will be issued in due course.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.